{"gene":"ADRA2A","run_date":"2026-06-09T22:02:42","timeline":{"discoveries":[{"year":2016,"finding":"A heterozygous gain-of-function mutation in ADRA2A (p.Leu68Phe) causes atypical familial partial lipodystrophy. Compared to wild-type ADRA2A overexpressed in HEK-293 cells and differentiated 3T3-L1 adipocytes, the mutant ADRA2A produced more cAMP and glycerol and was resistant to the effects of the α2-adrenergic receptor agonist clonidine and antagonist yohimbine, indicating loss of normal inhibitory signaling. The mechanism is excessive lipolysis in some adipose tissue depots due to impaired receptor function.","method":"Whole-exome sequencing for variant identification; overexpression of wild-type vs. mutant ADRA2A in HEK-293 cells and 3T3-L1 adipocytes; cAMP and glycerol production assays; pharmacological challenge with clonidine and yohimbine","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro functional assay with mutagenesis (WT vs mutant construct), multiple orthogonal readouts (cAMP, glycerol, pharmacological rescue), single lab","pmids":["27376152"],"is_preprint":false},{"year":2018,"finding":"Dexmedetomidine (a specific ADRA2A agonist) promotes phosphorylation of ERK1/2 in astrocytes via ADRA2A. In a hypoxia/reoxygenation (H/R) model, Dex pretreatment increased ADRA2A expression and p-ERK1/2 levels; the effect on p-ERK1/2 was attenuated by the EGFR inhibitor AG1478, placing ADRA2A upstream of ERK1/2 phosphorylation in a neuroprotective pathway against cerebral ischemic injury.","method":"Primary cultured astrocyte H/R model and focal cerebral I/R rat model; western blotting for ADRA2A and p-ERK1/2; pharmacological inhibition with AG1478","journal":"Experimental and therapeutic medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo models with western blot and pharmacological inhibition, two orthogonal readouts, single lab","pmids":["30546415"],"is_preprint":false},{"year":2022,"finding":"Adra2a activation with clonidine decreased cAMP content, PKA activity, and expression/secretion of growth factors in adipose-derived stem cells (ASCs), while Adra2a knockdown in diabetic (T2D) ASCs showed the opposite — increased cAMP, PKA activity, and growth factor secretion — restoring wound-healing capability in a T2D mouse excisional wound model. This places ADRA2A as an inhibitor of the cAMP/PKA axis in ASCs.","method":"Lentivirus-mediated RNAi knockdown of Adra2a; clonidine pharmacological activation; ELISA for growth factors; cAMP and PKA activity assays; RT-qPCR; in vivo T2D mouse wound healing model","journal":"Stem cells international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and pharmacological gain-of-function with multiple biochemical readouts (cAMP, PKA, growth factors) and in vivo validation, single lab","pmids":["36420091"],"is_preprint":false},{"year":2017,"finding":"miR-34a binds the 3'UTR of ADRA2A and represses its expression. The minor allele at rs3750625 (located in the miR-34a seed-binding region of the ADRA2A 3'UTR) enhances miR-34a-mediated repression of ADRA2A, leading to reduced ADRA2A expression and increased acute musculoskeletal pain severity in stressed individuals.","method":"Luciferase reporter assay (miR-34a binding to ADRA2A 3'UTR with major and minor alleles); miR-34a transfection in IMR-32 neuroblastoma cells to measure ADRA2A expression changes; rat peripheral nerve tissue expression after forced swim stress; human cohort association study (MVC and sexual assault cohorts)","journal":"Pain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase assay confirms miRNA-target interaction, cell-based mRNA/protein quantification, and in vivo stress model, single lab but multiple orthogonal approaches","pmids":["27805929"],"is_preprint":false},{"year":2020,"finding":"The rs3750625 minor allele in the 3'UTR of ADRA2A promotes binding of miR-34a to ADRA2A, increasing repression and reducing ADRA2A mRNA and protein levels. Patients carrying the AC genotype (minor allele) had lower ADRA2A expression and worse ICU sleep quality compared to CC genotype carriers, establishing a regulatory mechanism linking this SNP to ADRA2A abundance via miR-34a.","method":"Luciferase reporter assay for miR-34a binding to ADRA2A 3'UTR (major and minor alleles); RT-qPCR and western blot for ADRA2A mRNA and protein in HCN-1A and U251 cells after miR-34a precursor transfection; clinical comparison of sleep time/efficiency by genotype in ICU patients","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase and cell-based assays confirm miRNA-mediated regulation, replicated finding from a prior paper (PMID 27805929), single lab","pmids":["31922215"],"is_preprint":false},{"year":2015,"finding":"ADRA2A is expressed in osteoblasts and lining cells but not osteocytes. The rs553668 SNP significantly influences ADRA2A mRNA levels in human bone through mRNA stability. ADRA2A gene locus associates with bone remodelling markers (BMD, CTX, Cathepsin K, preosteocalcin), and neurological signalling through ADRA2A in osteoblasts results in bone resorption.","method":"Real-time PCR and immunohistochemistry for receptor localization in bone cells; luciferase reporter assay in HOS cells for SNP functionality; qPCR expression analysis on bone samples; genetic association study in 661 patients with osteoporosis","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — luciferase reporter and mRNA quantification confirm functional SNP effect on expression, cell-type localization by IHC and PCR, single lab with multiple approaches","pmids":["25818344"],"is_preprint":false},{"year":2023,"finding":"ADRA2A activation (by agonists xylazine, dexmedetomidine, clonidine, or genetic overexpression) reduced ovarian cancer cell viability and enhanced carboplatin cytotoxicity in multiple OvCa cell lines (TYKnu, CAOV3, OVCAR8), establishing that ADRA2A activation promotes chemosensitization in ovarian cancer.","method":"High-throughput screening of FDA-approved compounds; validation with three ADRA2A agonists in multiple cell lines using two independent viability assays; genetic overexpression of ADRA2A","journal":"Current issues in molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic overexpression plus pharmacological agonism with multiple agonists and multiple cell lines, but single lab","pmids":["38132444"],"is_preprint":false},{"year":2024,"finding":"ADRA2A transgene expression and ADRA2A agonist treatment inhibit PDAC cell invasion in vitro. ADRA2A-high conditions downregulate basal-like/squamous gene expression signatures and upregulate classical/progenitor signatures in PDAC cell lines and patient cohorts, and are associated with suppressed amino acid and carnitine/acylcarnitine metabolism characteristic of the classical/progenitor subtype.","method":"ADRA2A transgene overexpression in PDAC cell lines; ADRA2A agonist treatment; invasion assays; transcriptome analysis; metabolome analysis in patient cohort and cell lines","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgene overexpression and pharmacological activation with invasion assay and transcriptomic/metabolomic readouts, single lab","pmids":["39136088"],"is_preprint":false},{"year":2025,"finding":"ADRA2A knockdown in LPS-treated BEAS-2B airway epithelial cells reduced inflammation (pro-inflammatory cytokines) and apoptosis, while overexpression exacerbated these effects. In an OVA-induced asthma mouse model, ADRA2A knockdown reduced airway hyperresponsiveness, pulmonary edema, and inflammatory cell infiltration. Mechanistically, phosphorylation of ERK1/2 was reduced following ADRA2A knockdown both in vitro and in vivo, placing ADRA2A upstream of ERK1/2 in the asthmatic airway inflammatory pathway.","method":"siRNA knockdown and overexpression of ADRA2A in BEAS-2B cells; LPS stimulation; cytokine measurement; apoptosis assay; OVA-induced asthma mouse model with ADRA2A knockdown; western blotting for p-ERK1/2","journal":"Journal of inflammation (London, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (knockdown) and gain-of-function (overexpression) with in vitro and in vivo validation, ERK1/2 phosphorylation as mechanistic readout, single lab","pmids":["41299456"],"is_preprint":false},{"year":2026,"finding":"Sedative, hypnotic, and hypothermic effects of the α2-agonist dexmedetomidine are neuronally mediated via ADRA2A. Pan-neuronal (Snap25-Cre) Adra2a knockout mice showed resistance to all temperature, sedative, and hypnotic endpoints and blocked dexmedetomidine-induced EEG delta power increase. Adrenergic neuron (Dbh-Cre) Adra2a knockout showed resistance to hypnosis and moderate resistance to hypothermia/coordination impairment. GABAergic neuron (Vgat-Cre) Adra2a knockout showed resistance only to impairment of spontaneous movement, dissociating different dimensions of sedation to specific neuronal populations.","method":"CRISPR/Cas9 conditional Adra2a knockout mice; cell-type-specific Cre lines (Snap25, Dbh, Vgat); fluorescent in-situ hybridization to confirm mRNA reduction; dexmedetomidine challenge; righting reflex, rotarod, beam break, and EEG recording","journal":"bioRxiv : the preprint server for biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional cell-type-specific KO with multiple behavioral and EEG readouts, rigorous genetic dissection, but preprint (not yet peer-reviewed)","pmids":["42039552"],"is_preprint":true},{"year":2023,"finding":"ADRA2A upregulation by platycodin D in RL95-2 endometrial cancer cells inhibited cell proliferation, invasion, and migration and reduced PI3K/Akt pathway activation. sh-RNA knockdown of ADRA2A attenuated these effects of platycodin D, placing ADRA2A upstream of the PI3K/Akt pathway as an inhibitor of cancer cell invasiveness.","method":"Platycodin D treatment; shRNA knockdown of ADRA2A; RT-qPCR and western blot for ADRA2A and PI3K/Akt pathway components; CCK-8, MTT, colony formation, wound healing, and Transwell invasion assays","journal":"Oncology letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological upregulation + shRNA knockdown rescue experiment, single lab, indirect placement of ADRA2A in PI3K/Akt pathway without direct receptor-pathway interaction demonstration","pmids":["36909368"],"is_preprint":false},{"year":2025,"finding":"Human enterochromaffin (EC) cells derived from duodenal organoids express ADRA2A at the mRNA level, and functional assays demonstrated that adrenergic agonists elicit calcium, cAMP, and/or serotonin secretion responses in these cells, indicating ADRA2A is functionally expressed and mediates adrenergic regulation of EC cell serotonin release.","method":"CRISPR-Cas9-labeled human duodenal organoids; bulk RNA sequencing; calcium and cAMP imaging; 5-HT ELISA; electrophysiology","journal":"bioRxiv : the preprint server for biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — transcriptomic identification plus functional calcium/cAMP assays, but ADRA2A-specific role not isolated from other adrenergic receptors also expressed (ADRB1), preprint","pmids":["bio_10.1101_2025.03.17.643631"],"is_preprint":true}],"current_model":"ADRA2A encodes the α2A-adrenergic receptor, a Gi-coupled GPCR that acts as a presynaptic inhibitory feedback receptor to suppress cAMP production, inhibit ERK1/2 phosphorylation, reduce lipolysis, and modulate neurotransmitter release; gain-of-function mutations impair this inhibitory signaling causing excessive lipolysis, its activation in neurons mediates dexmedetomidine-induced sedation/hypnosis/hypothermia via cell-type-specific mechanisms (adrenergic neurons for hypnosis, GABAergic neurons for movement suppression), its expression level is post-transcriptionally regulated by miR-34a binding to the 3'UTR, and it functions in osteoblasts to mediate adrenergic regulation of bone resorption and in airway epithelium via the ERK1/2 pathway to modulate inflammatory responses."},"narrative":{"mechanistic_narrative":"ADRA2A encodes the α2A-adrenergic receptor, a Gi-coupled GPCR that acts as an inhibitory feedback node restraining the cAMP/PKA axis across multiple cell types [PMID:27376152, PMID:36420091]. In adipocytes, receptor activation suppresses cAMP and glycerol production; a heterozygous gain-of-function mutation (p.Leu68Phe) impairs this inhibitory signaling and causes atypical familial partial lipodystrophy through excessive lipolysis [PMID:27376152]. The same inhibition of the cAMP/PKA axis operates in adipose-derived stem cells, where ADRA2A activation lowers cAMP, PKA activity, and growth-factor secretion [PMID:36420091]. Beyond canonical Gi/cAMP coupling, ADRA2A activity is linked to ERK1/2 phosphorylation in astrocytes and airway epithelial cells, where it sits upstream of ERK1/2 in inflammatory and neuroprotective responses [PMID:30546415, PMID:41299456]. Receptor abundance is post-transcriptionally controlled by miR-34a binding to the ADRA2A 3'UTR, an interaction strengthened by the rs3750625 minor allele to reduce receptor expression [PMID:27805929, PMID:31922215], while an additional 3'UTR/mRNA-stability variant modulates ADRA2A levels in bone, where the receptor is expressed in osteoblasts and lining cells and contributes to adrenergic regulation of bone resorption [PMID:25818344]. ADRA2A activation also restrains tumor-cell aggressiveness, reducing viability and enhancing chemosensitivity in ovarian cancer and suppressing invasion in pancreatic cancer cells [PMID:38132444, PMID:39136088]. Cell-type-specific conditional knockout in mice establishes that the sedative, hypnotic, and hypothermic effects of the agonist dexmedetomidine are neuronally mediated through ADRA2A, with distinct neuronal populations governing separable dimensions of sedation [PMID:42039552].","teleology":[{"year":2015,"claim":"Established that ADRA2A is expressed in specific bone cell types and that a 3'UTR/regulatory variant tunes its expression, linking the receptor to adrenergic control of bone resorption.","evidence":"IHC and RT-PCR localization in osteoblasts/lining cells, luciferase reporter for SNP function, and association study in 661 osteoporosis patients","pmids":["25818344"],"confidence":"Medium","gaps":["Does not define the downstream signaling cascade coupling ADRA2A to resorption","Mechanism of rs553668 effect on mRNA stability not resolved at molecular level"]},{"year":2016,"claim":"Defined ADRA2A as an inhibitor of the cAMP/lipolysis axis in adipocytes and demonstrated that a gain-of-function mutation impairing inhibitory signaling causes a Mendelian lipodystrophy.","evidence":"Whole-exome sequencing plus WT vs. p.Leu68Phe overexpression in HEK-293 and 3T3-L1 with cAMP/glycerol assays and clonidine/yohimbine challenge","pmids":["27376152"],"confidence":"High","gaps":["Tissue-depot selectivity of excessive lipolysis not mechanistically explained","Structural basis of the gain-of-function mutation not determined"]},{"year":2017,"claim":"Identified miR-34a as a direct post-transcriptional repressor of ADRA2A and showed that a seed-region SNP (rs3750625) enhances repression, linking reduced receptor abundance to pain severity.","evidence":"Luciferase reporter with major/minor 3'UTR alleles, miR-34a transfection in IMR-32 cells, rat stress model, and human cohort association","pmids":["27805929"],"confidence":"Medium","gaps":["Causal chain from reduced receptor to pain phenotype not mechanistically dissected","Does not address whether miR-34a regulation operates in adrenergic neurons in vivo"]},{"year":2018,"claim":"Placed ADRA2A upstream of ERK1/2 phosphorylation in astrocytes, extending receptor signaling beyond Gi/cAMP into a neuroprotective MAPK pathway.","evidence":"Astrocyte H/R and rat cerebral I/R models with western blot for p-ERK1/2 and EGFR inhibition by AG1478","pmids":["30546415"],"confidence":"Medium","gaps":["Direct molecular link between receptor and EGFR transactivation not established","Whether ERK activation is protective causally vs. correlative not resolved"]},{"year":2020,"claim":"Replicated and extended the miR-34a/rs3750625 regulatory mechanism, tying lower ADRA2A expression to a distinct clinical phenotype (ICU sleep quality).","evidence":"Luciferase, RT-qPCR/western blot in HCN-1A and U251 cells, and clinical genotype-phenotype comparison","pmids":["31922215"],"confidence":"Medium","gaps":["Neuronal circuit linking receptor abundance to sleep not identified","No direct measurement of ADRA2A protein in patient tissue"]},{"year":2022,"claim":"Confirmed ADRA2A as a suppressor of the cAMP/PKA axis in adipose-derived stem cells and showed knockdown restores growth-factor secretion and wound healing in diabetes.","evidence":"Lentiviral RNAi knockdown and clonidine activation with cAMP/PKA/growth-factor readouts and an in vivo T2D wound model","pmids":["36420091"],"confidence":"Medium","gaps":["Which growth factors are the proximate drivers of wound healing not isolated","Receptor-effector coupling specificity not addressed"]},{"year":2023,"claim":"Demonstrated that ADRA2A activation restrains cancer-cell aggressiveness, reducing ovarian cancer viability/chemoresistance and inhibiting endometrial cancer invasion via PI3K/Akt.","evidence":"Compound screening and ADRA2A overexpression/agonism in ovarian lines; platycodin D upregulation with shRNA rescue and PI3K/Akt readouts in RL95-2 cells","pmids":["38132444","36909368"],"confidence":"Medium","gaps":["Direct receptor-to-PI3K/Akt coupling not biochemically shown (Low-confidence placement)","Endometrial finding is pharmacological/indirect, not a direct receptor mechanism"]},{"year":2024,"claim":"Linked ADRA2A activity to PDAC subtype identity, showing high receptor activity favors a classical/progenitor transcriptional and metabolic state with reduced invasion.","evidence":"ADRA2A transgene overexpression and agonist treatment with invasion assays, transcriptomics, and metabolomics in cell lines and patient cohorts","pmids":["39136088"],"confidence":"Medium","gaps":["Signaling intermediates driving the subtype switch not defined","Causality between metabolic shift and invasion suppression not established"]},{"year":2025,"claim":"Placed ADRA2A upstream of ERK1/2 in airway inflammation, with bidirectional knockdown/overexpression establishing it as a pro-inflammatory driver in asthma.","evidence":"siRNA/overexpression in LPS-treated BEAS-2B cells and OVA-induced asthma mouse model with cytokine, apoptosis, and p-ERK1/2 readouts","pmids":["41299456"],"confidence":"Medium","gaps":["Endogenous ligand driving airway ADRA2A-ERK signaling not identified","Mechanism connecting ERK to apoptosis and cytokine output not dissected"]},{"year":2026,"claim":"Dissected the neuronal basis of dexmedetomidine action, showing ADRA2A in distinct neuronal populations mediates separable dimensions of sedation, hypnosis, and hypothermia.","evidence":"CRISPR conditional Adra2a knockout with Snap25/Dbh/Vgat Cre lines, FISH validation, and behavioral/EEG endpoints (preprint)","pmids":["42039552"],"confidence":"Medium","gaps":["Preprint, not yet peer-reviewed","Downstream circuit and signaling effectors within each neuronal population not defined"]},{"year":null,"claim":"How a single Gi-coupled receptor selects between cAMP suppression, ERK activation, and PI3K/Akt modulation in a cell-type-specific manner remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural or biased-signaling framework links receptor conformation to divergent effector outputs","Endogenous ligands and co-receptors in non-neuronal contexts unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,8]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08913","full_name":"Alpha-2A adrenergic receptor","aliases":["Alpha-2 adrenergic receptor subtype C10","Alpha-2A adrenoreceptor","Alpha-2A adrenoceptor","Alpha-2AAR"],"length_aa":465,"mass_kda":50.6,"function":"Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression (PubMed:2170371, PubMed:23105096, PubMed:2568356, PubMed:35245122, PubMed:27376152). Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release (PubMed:2568356, PubMed:27376152). ADRA2A and ADRA2C mediates the presynaptic feedback inhibition of neurotransmitter release from noradrenergic nerve terminals in sympathetic and central nervous systems. ADRA2A inhibits transmitter release at high stimulation frequencies, whereas ADRA2C modulates neurotransmission at lower levels of nerve activity (By similarity). The rank order of potency for agonists of ADRA2A is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol (PubMed:2170371, PubMed:2568356)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P08913/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADRA2A","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADRA2A","total_profiled":1310},"omim":[{"mim_id":"620679","title":"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 8; FPLD8","url":"https://www.omim.org/entry/620679"},{"mim_id":"608120","title":"PARVIN, ALPHA; PARVA","url":"https://www.omim.org/entry/608120"},{"mim_id":"601768","title":"SH3 DOMAIN, GRB2-LIKE, 1; SH3GL1","url":"https://www.omim.org/entry/601768"},{"mim_id":"151660","title":"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","url":"https://www.omim.org/entry/151660"},{"mim_id":"143465","title":"ATTENTION DEFICIT-HYPERACTIVITY DISORDER; ADHD","url":"https://www.omim.org/entry/143465"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":46.9}],"url":"https://www.proteinatlas.org/search/ADRA2A"},"hgnc":{"alias_symbol":["ADRAR"],"prev_symbol":["ADRA2","ADRA2R"]},"alphafold":{"accession":"P08913","domains":[{"cath_id":"1.20.1070.10","chopping":"46-243_377-458","consensus_level":"high","plddt":91.2161,"start":46,"end":458}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08913","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08913-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08913-F1-predicted_aligned_error_v6.png","plddt_mean":70.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADRA2A","jax_strain_url":"https://www.jax.org/strain/search?query=ADRA2A"},"sequence":{"accession":"P08913","fasta_url":"https://rest.uniprot.org/uniprotkb/P08913.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08913/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08913"}},"corpus_meta":[{"pmid":"20419449","id":"PMC_20419449","title":"Variants at DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B loci are associated with reduced glucose-stimulated beta cell function in middle-aged Danish people.","date":"2010","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/20419449","citation_count":82,"is_preprint":false},{"pmid":"10334470","id":"PMC_10334470","title":"Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects.","date":"1999","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10334470","citation_count":79,"is_preprint":false},{"pmid":"12815749","id":"PMC_12815749","title":"Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder?","date":"2003","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12815749","citation_count":75,"is_preprint":false},{"pmid":"11886485","id":"PMC_11886485","title":"A C-1291G polymorphism in the alpha2A-adrenergic receptor gene (ADRA2A) promoter is associated with cortisol escape from dexamethasone and elevated glucose levels.","date":"2002","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11886485","citation_count":49,"is_preprint":false},{"pmid":"16869226","id":"PMC_16869226","title":"The adrenergic receptor alpha-2A gene (ADRA2A) and neuropsychological executive functions as putative endophenotypes for childhood ADHD.","date":"2006","source":"Cognitive, affective & behavioral neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16869226","citation_count":46,"is_preprint":false},{"pmid":"16178932","id":"PMC_16178932","title":"Attention deficit hyperactivity disorder with reading disabilities: preliminary genetic findings on the involvement of the ADRA2A gene.","date":"2005","source":"Journal of child psychology and psychiatry, and allied disciplines","url":"https://pubmed.ncbi.nlm.nih.gov/16178932","citation_count":42,"is_preprint":false},{"pmid":"16389583","id":"PMC_16389583","title":"Possible association of the alpha-2A adrenergic receptor gene (ADRA2A) with symptoms of attention-deficit/hyperactivity disorder.","date":"2006","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16389583","citation_count":36,"is_preprint":false},{"pmid":"22940547","id":"PMC_22940547","title":"Preliminary evidence for association between schizophrenia and polymorphisms in the regulatory Regions of the ADRA2A, DRD3 and SNAP-25 Genes.","date":"2012","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/22940547","citation_count":35,"is_preprint":false},{"pmid":"10909127","id":"PMC_10909127","title":"Association between the adrenergic alpha 2A receptor gene (ADRA2A) and measures of irritability, hostility, impulsivity and memory in normal subjects.","date":"2000","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10909127","citation_count":35,"is_preprint":false},{"pmid":"12627476","id":"PMC_12627476","title":"A \"line item\" approach to the identification of genes involved in polygenic behavioral disorders: the adrenergic alpha2A (ADRA2A) gene.","date":"2003","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12627476","citation_count":30,"is_preprint":false},{"pmid":"21104443","id":"PMC_21104443","title":"The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21104443","citation_count":28,"is_preprint":false},{"pmid":"27376152","id":"PMC_27376152","title":"Whole-exome sequencing identifies ADRA2A mutation in atypical familial partial lipodystrophy.","date":"2016","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/27376152","citation_count":27,"is_preprint":false},{"pmid":"21455730","id":"PMC_21455730","title":"Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies.","date":"2011","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/21455730","citation_count":26,"is_preprint":false},{"pmid":"25818344","id":"PMC_25818344","title":"ADRA2A is involved in neuro-endocrine regulation of bone resorption.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25818344","citation_count":24,"is_preprint":false},{"pmid":"37828025","id":"PMC_37828025","title":"ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37828025","citation_count":19,"is_preprint":false},{"pmid":"16854373","id":"PMC_16854373","title":"Identification of ADRA2A polymorphisms related to shear-mediated platelet function.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16854373","citation_count":19,"is_preprint":false},{"pmid":"30791043","id":"PMC_30791043","title":"The relationship between MMP9 and ADRA2A gene polymorphisms and mothers-newborns' nutritional status: an exploratory path model (STROBE compliant article).","date":"2019","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/30791043","citation_count":18,"is_preprint":false},{"pmid":"24917480","id":"PMC_24917480","title":"Association Between SLC6A4 Serotonin Transporter Gene Lainked Polymorphic Region and ADRA2A -1291C>G and Irritable Bowel Syndrome in Korea.","date":"2014","source":"Journal of neurogastroenterology and motility","url":"https://pubmed.ncbi.nlm.nih.gov/24917480","citation_count":17,"is_preprint":false},{"pmid":"17612790","id":"PMC_17612790","title":"Tobacco smoking and the ADRA2A C-1291G polymorphism.","date":"2007","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/17612790","citation_count":17,"is_preprint":false},{"pmid":"20864182","id":"PMC_20864182","title":"ADRA2A polymorphisms and ADHD in adults: possible mediating effect of personality.","date":"2010","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/20864182","citation_count":16,"is_preprint":false},{"pmid":"30009772","id":"PMC_30009772","title":"Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).","date":"2018","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30009772","citation_count":16,"is_preprint":false},{"pmid":"24424705","id":"PMC_24424705","title":"Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.","date":"2013","source":"Human psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24424705","citation_count":13,"is_preprint":false},{"pmid":"21063237","id":"PMC_21063237","title":"Effect of ADRA2A and BDNF gene-gene interaction on the continuous performance test phenotype.","date":"2011","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21063237","citation_count":12,"is_preprint":false},{"pmid":"26563278","id":"PMC_26563278","title":"ADRA2A Germline Gene Polymorphism is Associated to the Severity, but not to the Risk, of Breast Cancer.","date":"2015","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/26563278","citation_count":12,"is_preprint":false},{"pmid":"26234518","id":"PMC_26234518","title":"Perception of emotion in facial stimuli: The interaction of ADRA2A and COMT genotypes, and sex.","date":"2015","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/26234518","citation_count":12,"is_preprint":false},{"pmid":"30546415","id":"PMC_30546415","title":"Neuroprotective role of dexmedetomidine pretreatment in cerebral ischemia injury via ADRA2A-mediated phosphorylation of ERK1/2 in adult rats.","date":"2018","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30546415","citation_count":12,"is_preprint":false},{"pmid":"24522021","id":"PMC_24522021","title":"Interactive effect of MTHFR and ADRA2A gene polymorphisms on pathogenesis of schizophrenia.","date":"2013","source":"Neuro endocrinology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24522021","citation_count":11,"is_preprint":false},{"pmid":"29800730","id":"PMC_29800730","title":"The ADRA2A rs553668 variant is associated with type 2 diabetes and five variants were associated at nominal significance levels in a population-based case-control study from Mexico City.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29800730","citation_count":10,"is_preprint":false},{"pmid":"23153004","id":"PMC_23153004","title":"Evaluation of the association between the ADRA2A genetic polymorphisms and type 2 diabetes in a Chinese Han population.","date":"2012","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/23153004","citation_count":10,"is_preprint":false},{"pmid":"17034020","id":"PMC_17034020","title":"No association between ADRA2A polymorphisms and schizophrenia.","date":"2007","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17034020","citation_count":10,"is_preprint":false},{"pmid":"36420091","id":"PMC_36420091","title":"Knockdown of Adra2a Increases Secretion of Growth Factors and Wound Healing Ability in Diabetic Adipose-Derived Stem Cells.","date":"2022","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/36420091","citation_count":9,"is_preprint":false},{"pmid":"25110082","id":"PMC_25110082","title":"On statistical relationship between ADRA2A expression and the risk of breast cancer relapse.","date":"2014","source":"Bulletin of experimental biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25110082","citation_count":9,"is_preprint":false},{"pmid":"18842695","id":"PMC_18842695","title":"ADRA2A polymorphism and smoking in a Turkish population.","date":"2008","source":"Toxicology and industrial health","url":"https://pubmed.ncbi.nlm.nih.gov/18842695","citation_count":9,"is_preprint":false},{"pmid":"27805929","id":"PMC_27805929","title":"Genetic variant rs3750625 in the 3'UTR of ADRA2A affects stress-dependent acute pain severity after trauma and alters a microRNA-34a regulatory site.","date":"2017","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/27805929","citation_count":9,"is_preprint":false},{"pmid":"22061269","id":"PMC_22061269","title":"The rs553668 polymorphism of the ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study.","date":"2012","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/22061269","citation_count":8,"is_preprint":false},{"pmid":"39136088","id":"PMC_39136088","title":"ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer.","date":"2024","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/39136088","citation_count":7,"is_preprint":false},{"pmid":"27186390","id":"PMC_27186390","title":"Evaluation of Association of ADRA2A rs553668 and ACE I/D Gene Polymorphisms with Obesity Traits in the Setapak Population, Malaysia.","date":"2016","source":"Iranian Red Crescent medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27186390","citation_count":6,"is_preprint":false},{"pmid":"32256718","id":"PMC_32256718","title":"Effect of ADRA2A gene polymorphisms on the anesthetic and analgesic effects of dexmedetomidine in Chinese Han women with cesarean section.","date":"2020","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32256718","citation_count":6,"is_preprint":false},{"pmid":"23751900","id":"PMC_23751900","title":"No association between MspI allele of the ADRA2A polymorphism and ADHD: meta-analysis of family-based studies.","date":"2013","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23751900","citation_count":6,"is_preprint":false},{"pmid":"38132444","id":"PMC_38132444","title":"Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines.","date":"2023","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38132444","citation_count":6,"is_preprint":false},{"pmid":"34948773","id":"PMC_34948773","title":"The Predictive Role of ADRA2A rs1800544 and HTR3B rs3758987 Polymorphisms in Motion Sickness Susceptibility.","date":"2021","source":"International journal of environmental research and public health","url":"https://pubmed.ncbi.nlm.nih.gov/34948773","citation_count":5,"is_preprint":false},{"pmid":"36909368","id":"PMC_36909368","title":"Platycodin D inhibits the proliferation, invasion and migration of endometrial cancer cells by blocking the PI3K/Akt signaling pathway via ADRA2A upregulation.","date":"2023","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/36909368","citation_count":5,"is_preprint":false},{"pmid":"33915198","id":"PMC_33915198","title":"The effect of alpha-2A adrenergic receptor (ADRA2A) genetic polymorphisms on the depth of sedation of dexmedetomidine: a genetic observational pilot study.","date":"2021","source":"Brazilian journal of anesthesiology (Elsevier)","url":"https://pubmed.ncbi.nlm.nih.gov/33915198","citation_count":5,"is_preprint":false},{"pmid":"38857067","id":"PMC_38857067","title":"Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38857067","citation_count":4,"is_preprint":false},{"pmid":"39278467","id":"PMC_39278467","title":"The implication of ADRA2A and AVPRIB gene variants in the aetiology of stress-related bipolar disorder.","date":"2024","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/39278467","citation_count":4,"is_preprint":false},{"pmid":"29482474","id":"PMC_29482474","title":"Potential Role of ADRA2A Genetic Variants in the Etiology of ADHD Comorbid With Tic Disorders.","date":"2018","source":"Journal of attention disorders","url":"https://pubmed.ncbi.nlm.nih.gov/29482474","citation_count":4,"is_preprint":false},{"pmid":"35429176","id":"PMC_35429176","title":"A pilot study of ADRA2A genotype association with doses of dexmedetomidine for sedation in pediatric patients.","date":"2022","source":"Pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/35429176","citation_count":4,"is_preprint":false},{"pmid":"24178896","id":"PMC_24178896","title":"Sequence analysis of the ADRA2A coding region in children affected by attention deficit hyperactivity disorder.","date":"2013","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/24178896","citation_count":4,"is_preprint":false},{"pmid":"9344667","id":"PMC_9344667","title":"Detailed physical analysis of a 1.5-megabase YAC contig containing the MXI1 and ADRA2A genes.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9344667","citation_count":4,"is_preprint":false},{"pmid":"26410938","id":"PMC_26410938","title":"[Genetic Association of ADRA2A and ADRB3 Genes with Metabolic Syndrome among the Tatars].","date":"2015","source":"Genetika","url":"https://pubmed.ncbi.nlm.nih.gov/26410938","citation_count":4,"is_preprint":false},{"pmid":"31922215","id":"PMC_31922215","title":"Genetic variant rs3750625 in the 3'UTR of ADRA2A affects the sleep quality of patients in the ICU by promoting miR‑34a binding to ADRA2A.","date":"2020","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31922215","citation_count":3,"is_preprint":false},{"pmid":"25926111","id":"PMC_25926111","title":"The rs10885122 polymorphism of the adrenoceptor alpha 2A (ADRA2A) gene in Euro-Brazilians with type 2 diabetes mellitus.","date":"2015","source":"Archives of endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25926111","citation_count":3,"is_preprint":false},{"pmid":"40564659","id":"PMC_40564659","title":"The Role of Gene-Gene Interaction Between ADRA2A and SLC6A2 Polymorphisms in Attention System and Treatment Outcomes for Children with ADHD.","date":"2025","source":"Children (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40564659","citation_count":1,"is_preprint":false},{"pmid":"36325160","id":"PMC_36325160","title":"Review and Meta-analysis on the Impact of the ADRA2A Variant rs1800544 on Methylphenidate Outcomes in Attention-Deficit/Hyperactivity Disorder.","date":"2021","source":"Biological psychiatry global open science","url":"https://pubmed.ncbi.nlm.nih.gov/36325160","citation_count":1,"is_preprint":false},{"pmid":"38903083","id":"PMC_38903083","title":"ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38903083","citation_count":0,"is_preprint":false},{"pmid":"41299456","id":"PMC_41299456","title":"ADRA2A contributes to airway inflammation and apoptosis in asthma through the ERK signaling in vitro and in vivo.","date":"2025","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/41299456","citation_count":0,"is_preprint":false},{"pmid":"2072852","id":"PMC_2072852","title":"[Nutritional disorders and primary health care. Analysis and strategic approach in the Mauritanian Adrar region].","date":"1991","source":"Medecine tropicale : revue du Corps de sante colonial","url":"https://pubmed.ncbi.nlm.nih.gov/2072852","citation_count":0,"is_preprint":false},{"pmid":"40283179","id":"PMC_40283179","title":"A Pilot Study on the Correlation Between Psychometric Traits and ADRA2A rs1800544 Polymorphism in Fencing Athletes.","date":"2025","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40283179","citation_count":0,"is_preprint":false},{"pmid":"42039552","id":"PMC_42039552","title":"A Novel Conditional Adra2a-Knockout Mouse Line Reveals Cell-specific Contributions to Specific Dimensions of Sedation.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/42039552","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.17.683095","title":"Shared and reinforcer-specific alterations in the CRH and noradrenergic systems following short- and long-term withdrawal from cocaine, heroin, and sucrose self-administration","date":"2025-10-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.17.683095","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.17.643631","title":"Mechanisms of Activation and Serotonin release from Human Enterochromaffin Cells","date":"2025-03-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.17.643631","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":33403,"output_tokens":3960,"usd":0.079805,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11700,"output_tokens":3562,"usd":0.073775,"stage2_stop_reason":"end_turn"},"total_usd":0.15358,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"A heterozygous gain-of-function mutation in ADRA2A (p.Leu68Phe) causes atypical familial partial lipodystrophy. Compared to wild-type ADRA2A overexpressed in HEK-293 cells and differentiated 3T3-L1 adipocytes, the mutant ADRA2A produced more cAMP and glycerol and was resistant to the effects of the α2-adrenergic receptor agonist clonidine and antagonist yohimbine, indicating loss of normal inhibitory signaling. The mechanism is excessive lipolysis in some adipose tissue depots due to impaired receptor function.\",\n      \"method\": \"Whole-exome sequencing for variant identification; overexpression of wild-type vs. mutant ADRA2A in HEK-293 cells and 3T3-L1 adipocytes; cAMP and glycerol production assays; pharmacological challenge with clonidine and yohimbine\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro functional assay with mutagenesis (WT vs mutant construct), multiple orthogonal readouts (cAMP, glycerol, pharmacological rescue), single lab\",\n      \"pmids\": [\"27376152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Dexmedetomidine (a specific ADRA2A agonist) promotes phosphorylation of ERK1/2 in astrocytes via ADRA2A. In a hypoxia/reoxygenation (H/R) model, Dex pretreatment increased ADRA2A expression and p-ERK1/2 levels; the effect on p-ERK1/2 was attenuated by the EGFR inhibitor AG1478, placing ADRA2A upstream of ERK1/2 phosphorylation in a neuroprotective pathway against cerebral ischemic injury.\",\n      \"method\": \"Primary cultured astrocyte H/R model and focal cerebral I/R rat model; western blotting for ADRA2A and p-ERK1/2; pharmacological inhibition with AG1478\",\n      \"journal\": \"Experimental and therapeutic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo models with western blot and pharmacological inhibition, two orthogonal readouts, single lab\",\n      \"pmids\": [\"30546415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Adra2a activation with clonidine decreased cAMP content, PKA activity, and expression/secretion of growth factors in adipose-derived stem cells (ASCs), while Adra2a knockdown in diabetic (T2D) ASCs showed the opposite — increased cAMP, PKA activity, and growth factor secretion — restoring wound-healing capability in a T2D mouse excisional wound model. This places ADRA2A as an inhibitor of the cAMP/PKA axis in ASCs.\",\n      \"method\": \"Lentivirus-mediated RNAi knockdown of Adra2a; clonidine pharmacological activation; ELISA for growth factors; cAMP and PKA activity assays; RT-qPCR; in vivo T2D mouse wound healing model\",\n      \"journal\": \"Stem cells international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and pharmacological gain-of-function with multiple biochemical readouts (cAMP, PKA, growth factors) and in vivo validation, single lab\",\n      \"pmids\": [\"36420091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-34a binds the 3'UTR of ADRA2A and represses its expression. The minor allele at rs3750625 (located in the miR-34a seed-binding region of the ADRA2A 3'UTR) enhances miR-34a-mediated repression of ADRA2A, leading to reduced ADRA2A expression and increased acute musculoskeletal pain severity in stressed individuals.\",\n      \"method\": \"Luciferase reporter assay (miR-34a binding to ADRA2A 3'UTR with major and minor alleles); miR-34a transfection in IMR-32 neuroblastoma cells to measure ADRA2A expression changes; rat peripheral nerve tissue expression after forced swim stress; human cohort association study (MVC and sexual assault cohorts)\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase assay confirms miRNA-target interaction, cell-based mRNA/protein quantification, and in vivo stress model, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"27805929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The rs3750625 minor allele in the 3'UTR of ADRA2A promotes binding of miR-34a to ADRA2A, increasing repression and reducing ADRA2A mRNA and protein levels. Patients carrying the AC genotype (minor allele) had lower ADRA2A expression and worse ICU sleep quality compared to CC genotype carriers, establishing a regulatory mechanism linking this SNP to ADRA2A abundance via miR-34a.\",\n      \"method\": \"Luciferase reporter assay for miR-34a binding to ADRA2A 3'UTR (major and minor alleles); RT-qPCR and western blot for ADRA2A mRNA and protein in HCN-1A and U251 cells after miR-34a precursor transfection; clinical comparison of sleep time/efficiency by genotype in ICU patients\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase and cell-based assays confirm miRNA-mediated regulation, replicated finding from a prior paper (PMID 27805929), single lab\",\n      \"pmids\": [\"31922215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADRA2A is expressed in osteoblasts and lining cells but not osteocytes. The rs553668 SNP significantly influences ADRA2A mRNA levels in human bone through mRNA stability. ADRA2A gene locus associates with bone remodelling markers (BMD, CTX, Cathepsin K, preosteocalcin), and neurological signalling through ADRA2A in osteoblasts results in bone resorption.\",\n      \"method\": \"Real-time PCR and immunohistochemistry for receptor localization in bone cells; luciferase reporter assay in HOS cells for SNP functionality; qPCR expression analysis on bone samples; genetic association study in 661 patients with osteoporosis\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — luciferase reporter and mRNA quantification confirm functional SNP effect on expression, cell-type localization by IHC and PCR, single lab with multiple approaches\",\n      \"pmids\": [\"25818344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADRA2A activation (by agonists xylazine, dexmedetomidine, clonidine, or genetic overexpression) reduced ovarian cancer cell viability and enhanced carboplatin cytotoxicity in multiple OvCa cell lines (TYKnu, CAOV3, OVCAR8), establishing that ADRA2A activation promotes chemosensitization in ovarian cancer.\",\n      \"method\": \"High-throughput screening of FDA-approved compounds; validation with three ADRA2A agonists in multiple cell lines using two independent viability assays; genetic overexpression of ADRA2A\",\n      \"journal\": \"Current issues in molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic overexpression plus pharmacological agonism with multiple agonists and multiple cell lines, but single lab\",\n      \"pmids\": [\"38132444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADRA2A transgene expression and ADRA2A agonist treatment inhibit PDAC cell invasion in vitro. ADRA2A-high conditions downregulate basal-like/squamous gene expression signatures and upregulate classical/progenitor signatures in PDAC cell lines and patient cohorts, and are associated with suppressed amino acid and carnitine/acylcarnitine metabolism characteristic of the classical/progenitor subtype.\",\n      \"method\": \"ADRA2A transgene overexpression in PDAC cell lines; ADRA2A agonist treatment; invasion assays; transcriptome analysis; metabolome analysis in patient cohort and cell lines\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgene overexpression and pharmacological activation with invasion assay and transcriptomic/metabolomic readouts, single lab\",\n      \"pmids\": [\"39136088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ADRA2A knockdown in LPS-treated BEAS-2B airway epithelial cells reduced inflammation (pro-inflammatory cytokines) and apoptosis, while overexpression exacerbated these effects. In an OVA-induced asthma mouse model, ADRA2A knockdown reduced airway hyperresponsiveness, pulmonary edema, and inflammatory cell infiltration. Mechanistically, phosphorylation of ERK1/2 was reduced following ADRA2A knockdown both in vitro and in vivo, placing ADRA2A upstream of ERK1/2 in the asthmatic airway inflammatory pathway.\",\n      \"method\": \"siRNA knockdown and overexpression of ADRA2A in BEAS-2B cells; LPS stimulation; cytokine measurement; apoptosis assay; OVA-induced asthma mouse model with ADRA2A knockdown; western blotting for p-ERK1/2\",\n      \"journal\": \"Journal of inflammation (London, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (knockdown) and gain-of-function (overexpression) with in vitro and in vivo validation, ERK1/2 phosphorylation as mechanistic readout, single lab\",\n      \"pmids\": [\"41299456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Sedative, hypnotic, and hypothermic effects of the α2-agonist dexmedetomidine are neuronally mediated via ADRA2A. Pan-neuronal (Snap25-Cre) Adra2a knockout mice showed resistance to all temperature, sedative, and hypnotic endpoints and blocked dexmedetomidine-induced EEG delta power increase. Adrenergic neuron (Dbh-Cre) Adra2a knockout showed resistance to hypnosis and moderate resistance to hypothermia/coordination impairment. GABAergic neuron (Vgat-Cre) Adra2a knockout showed resistance only to impairment of spontaneous movement, dissociating different dimensions of sedation to specific neuronal populations.\",\n      \"method\": \"CRISPR/Cas9 conditional Adra2a knockout mice; cell-type-specific Cre lines (Snap25, Dbh, Vgat); fluorescent in-situ hybridization to confirm mRNA reduction; dexmedetomidine challenge; righting reflex, rotarod, beam break, and EEG recording\",\n      \"journal\": \"bioRxiv : the preprint server for biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional cell-type-specific KO with multiple behavioral and EEG readouts, rigorous genetic dissection, but preprint (not yet peer-reviewed)\",\n      \"pmids\": [\"42039552\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADRA2A upregulation by platycodin D in RL95-2 endometrial cancer cells inhibited cell proliferation, invasion, and migration and reduced PI3K/Akt pathway activation. sh-RNA knockdown of ADRA2A attenuated these effects of platycodin D, placing ADRA2A upstream of the PI3K/Akt pathway as an inhibitor of cancer cell invasiveness.\",\n      \"method\": \"Platycodin D treatment; shRNA knockdown of ADRA2A; RT-qPCR and western blot for ADRA2A and PI3K/Akt pathway components; CCK-8, MTT, colony formation, wound healing, and Transwell invasion assays\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological upregulation + shRNA knockdown rescue experiment, single lab, indirect placement of ADRA2A in PI3K/Akt pathway without direct receptor-pathway interaction demonstration\",\n      \"pmids\": [\"36909368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Human enterochromaffin (EC) cells derived from duodenal organoids express ADRA2A at the mRNA level, and functional assays demonstrated that adrenergic agonists elicit calcium, cAMP, and/or serotonin secretion responses in these cells, indicating ADRA2A is functionally expressed and mediates adrenergic regulation of EC cell serotonin release.\",\n      \"method\": \"CRISPR-Cas9-labeled human duodenal organoids; bulk RNA sequencing; calcium and cAMP imaging; 5-HT ELISA; electrophysiology\",\n      \"journal\": \"bioRxiv : the preprint server for biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — transcriptomic identification plus functional calcium/cAMP assays, but ADRA2A-specific role not isolated from other adrenergic receptors also expressed (ADRB1), preprint\",\n      \"pmids\": [\"bio_10.1101_2025.03.17.643631\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ADRA2A encodes the α2A-adrenergic receptor, a Gi-coupled GPCR that acts as a presynaptic inhibitory feedback receptor to suppress cAMP production, inhibit ERK1/2 phosphorylation, reduce lipolysis, and modulate neurotransmitter release; gain-of-function mutations impair this inhibitory signaling causing excessive lipolysis, its activation in neurons mediates dexmedetomidine-induced sedation/hypnosis/hypothermia via cell-type-specific mechanisms (adrenergic neurons for hypnosis, GABAergic neurons for movement suppression), its expression level is post-transcriptionally regulated by miR-34a binding to the 3'UTR, and it functions in osteoblasts to mediate adrenergic regulation of bone resorption and in airway epithelium via the ERK1/2 pathway to modulate inflammatory responses.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADRA2A encodes the α2A-adrenergic receptor, a Gi-coupled GPCR that acts as an inhibitory feedback node restraining the cAMP/PKA axis across multiple cell types [#0, #2]. In adipocytes, receptor activation suppresses cAMP and glycerol production; a heterozygous gain-of-function mutation (p.Leu68Phe) impairs this inhibitory signaling and causes atypical familial partial lipodystrophy through excessive lipolysis [#0]. The same inhibition of the cAMP/PKA axis operates in adipose-derived stem cells, where ADRA2A activation lowers cAMP, PKA activity, and growth-factor secretion [#2]. Beyond canonical Gi/cAMP coupling, ADRA2A activity is linked to ERK1/2 phosphorylation in astrocytes and airway epithelial cells, where it sits upstream of ERK1/2 in inflammatory and neuroprotective responses [#1, #8]. Receptor abundance is post-transcriptionally controlled by miR-34a binding to the ADRA2A 3'UTR, an interaction strengthened by the rs3750625 minor allele to reduce receptor expression [#3, #4], while an additional 3'UTR/mRNA-stability variant modulates ADRA2A levels in bone, where the receptor is expressed in osteoblasts and lining cells and contributes to adrenergic regulation of bone resorption [#5]. ADRA2A activation also restrains tumor-cell aggressiveness, reducing viability and enhancing chemosensitivity in ovarian cancer and suppressing invasion in pancreatic cancer cells [#6, #7]. Cell-type-specific conditional knockout in mice establishes that the sedative, hypnotic, and hypothermic effects of the agonist dexmedetomidine are neuronally mediated through ADRA2A, with distinct neuronal populations governing separable dimensions of sedation [#9].\",\n  \"teleology\": [\n    {\n      \"year\": 2015,\n      \"claim\": \"Established that ADRA2A is expressed in specific bone cell types and that a 3'UTR/regulatory variant tunes its expression, linking the receptor to adrenergic control of bone resorption.\",\n      \"evidence\": \"IHC and RT-PCR localization in osteoblasts/lining cells, luciferase reporter for SNP function, and association study in 661 osteoporosis patients\",\n      \"pmids\": [\"25818344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not define the downstream signaling cascade coupling ADRA2A to resorption\", \"Mechanism of rs553668 effect on mRNA stability not resolved at molecular level\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined ADRA2A as an inhibitor of the cAMP/lipolysis axis in adipocytes and demonstrated that a gain-of-function mutation impairing inhibitory signaling causes a Mendelian lipodystrophy.\",\n      \"evidence\": \"Whole-exome sequencing plus WT vs. p.Leu68Phe overexpression in HEK-293 and 3T3-L1 with cAMP/glycerol assays and clonidine/yohimbine challenge\",\n      \"pmids\": [\"27376152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-depot selectivity of excessive lipolysis not mechanistically explained\", \"Structural basis of the gain-of-function mutation not determined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified miR-34a as a direct post-transcriptional repressor of ADRA2A and showed that a seed-region SNP (rs3750625) enhances repression, linking reduced receptor abundance to pain severity.\",\n      \"evidence\": \"Luciferase reporter with major/minor 3'UTR alleles, miR-34a transfection in IMR-32 cells, rat stress model, and human cohort association\",\n      \"pmids\": [\"27805929\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal chain from reduced receptor to pain phenotype not mechanistically dissected\", \"Does not address whether miR-34a regulation operates in adrenergic neurons in vivo\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed ADRA2A upstream of ERK1/2 phosphorylation in astrocytes, extending receptor signaling beyond Gi/cAMP into a neuroprotective MAPK pathway.\",\n      \"evidence\": \"Astrocyte H/R and rat cerebral I/R models with western blot for p-ERK1/2 and EGFR inhibition by AG1478\",\n      \"pmids\": [\"30546415\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between receptor and EGFR transactivation not established\", \"Whether ERK activation is protective causally vs. correlative not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Replicated and extended the miR-34a/rs3750625 regulatory mechanism, tying lower ADRA2A expression to a distinct clinical phenotype (ICU sleep quality).\",\n      \"evidence\": \"Luciferase, RT-qPCR/western blot in HCN-1A and U251 cells, and clinical genotype-phenotype comparison\",\n      \"pmids\": [\"31922215\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Neuronal circuit linking receptor abundance to sleep not identified\", \"No direct measurement of ADRA2A protein in patient tissue\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Confirmed ADRA2A as a suppressor of the cAMP/PKA axis in adipose-derived stem cells and showed knockdown restores growth-factor secretion and wound healing in diabetes.\",\n      \"evidence\": \"Lentiviral RNAi knockdown and clonidine activation with cAMP/PKA/growth-factor readouts and an in vivo T2D wound model\",\n      \"pmids\": [\"36420091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which growth factors are the proximate drivers of wound healing not isolated\", \"Receptor-effector coupling specificity not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated that ADRA2A activation restrains cancer-cell aggressiveness, reducing ovarian cancer viability/chemoresistance and inhibiting endometrial cancer invasion via PI3K/Akt.\",\n      \"evidence\": \"Compound screening and ADRA2A overexpression/agonism in ovarian lines; platycodin D upregulation with shRNA rescue and PI3K/Akt readouts in RL95-2 cells\",\n      \"pmids\": [\"38132444\", \"36909368\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor-to-PI3K/Akt coupling not biochemically shown (Low-confidence placement)\", \"Endometrial finding is pharmacological/indirect, not a direct receptor mechanism\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked ADRA2A activity to PDAC subtype identity, showing high receptor activity favors a classical/progenitor transcriptional and metabolic state with reduced invasion.\",\n      \"evidence\": \"ADRA2A transgene overexpression and agonist treatment with invasion assays, transcriptomics, and metabolomics in cell lines and patient cohorts\",\n      \"pmids\": [\"39136088\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling intermediates driving the subtype switch not defined\", \"Causality between metabolic shift and invasion suppression not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placed ADRA2A upstream of ERK1/2 in airway inflammation, with bidirectional knockdown/overexpression establishing it as a pro-inflammatory driver in asthma.\",\n      \"evidence\": \"siRNA/overexpression in LPS-treated BEAS-2B cells and OVA-induced asthma mouse model with cytokine, apoptosis, and p-ERK1/2 readouts\",\n      \"pmids\": [\"41299456\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous ligand driving airway ADRA2A-ERK signaling not identified\", \"Mechanism connecting ERK to apoptosis and cytokine output not dissected\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Dissected the neuronal basis of dexmedetomidine action, showing ADRA2A in distinct neuronal populations mediates separable dimensions of sedation, hypnosis, and hypothermia.\",\n      \"evidence\": \"CRISPR conditional Adra2a knockout with Snap25/Dbh/Vgat Cre lines, FISH validation, and behavioral/EEG endpoints (preprint)\",\n      \"pmids\": [\"42039552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer-reviewed\", \"Downstream circuit and signaling effectors within each neuronal population not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single Gi-coupled receptor selects between cAMP suppression, ERK activation, and PI3K/Akt modulation in a cell-type-specific manner remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural or biased-signaling framework links receptor conformation to divergent effector outputs\", \"Endogenous ligands and co-receptors in non-neuronal contexts unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 8]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}